Actively Recruiting
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
Led by University Hospital, Montpellier · Updated on 2025-07-10
60
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy. The main questions it aims to answer are: * Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients? Participants blood will be collected at several time points.
CONDITIONS
Official Title
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of at least 18 years old
- Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy
- Diagnosis of HCC established by imaging criteria (LI-RADSv2018) or histological evidence
- Advanced HCC defined by BCLC stages B and C
- Patients able to give oral consent
You will not qualify if you...
- Previous systemic anti-tumor treatment (immunotherapy, chemotherapy, or targeted therapy)
- Personal history of neoplasia within the last 5 years
- Personal history of systemic inflammatory diseases
- Receiving immunosuppressive treatment or therapy that could modify immunity (e.g., anti-TNF)
- Not affiliated with or not a beneficiary of a Social Security system
- Vulnerable persons as defined by article L1121-6 of the CSP
- Adults who are protected or unable to give consent according to article L1121-8 of the CSP
- Pregnant or breastfeeding women according to article L1121-5 of the CSP
- Inability to comply with follow-up due to transfer, poor motivation, compliance issues, or priority associated pathology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Montpellier
Montpellier, France
Actively Recruiting
Research Team
T
Thomas Bardol, M.D.
CONTACT
C
Catherine Guillemare
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here